OCUL · Ocular Therapeutix, Inc
$10.04
-0.06 (-0.59%)
At close · Aug 14
Market Cap
$2.20B
Shares
219.62M
Ocular Therapeutix, Inc Earnings Call Transcripts
Every quarterly earnings call for Ocular Therapeutix, Inc (OCUL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲79.6%
$13.19M
−$12.54M
'22 Q1
22-05-09
▲4.7%
$12.27M
−$18.77M
'22 Q2
22-08-08
▼1.5%
$11.96M
−$24.19M
'22 Q3
22-11-07
▲14.4%
$14.08M
−$15.54M
'22 Q4
23-01-06
▲1.4%
$13.37M
−$30.32M
'23 Q1
23-05-08
▲23.8%
$15.19M
−$20.68M
'23 Q2
23-08-07
▲26%
$15.08M
−$516,000
'23 Q3
23-11-07
▲10.5%
$14.77M
−$64.85M
'24 Q1
24-05-07
▲8.3%
$16.44M
−$43.78M
'24 Q2
24-08-07
▲2.3%
$15.43M
−$36.49M
'24 Q3
24-11-14
▲15.4%
$17.08M
−$48.39M
'24 Q4
25-03-03
▼18.1%
$13.46M
−$67.81M
'25 Q2
25-08-05
▼5.7%
$14.54M
−$69.42M
'25 Q3
25-11-04
▼22.4%
$13.25M
−$64.65M
'25 Q4
26-02-05
▲0.8%
$10.79M
−$88.61M
'26 Q1
26-05-05
LATEST
▲0.1%
$13.47M
−$78.76M
'26 Q2
26-08-03
Earnings call
FY26 · Q2
2026-08-03
Ocular Therapeutix, Inc Q2 FY2026 Earnings Call
Revenue
$13.47M
▲ 0.1% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Ocular Therapeutix, Inc Q1 FY2026 Earnings Call
Confident tone
X-Paxly SOL1 Phase 3 superiority in wet AMD
NDA submission and regulatory pathway
SOLAR confirmatory trial
Revenue
$10.79M
▲ 0.8% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Ocular Therapeutix, Inc Q4 FY2025 Earnings Call
Revenue
$13.25M*
▼ 22.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ocular Therapeutix, Inc Q3 FY2025 Earnings Call
Confident tone
AXPAXLI superiority label strategy
SOL-1 and SOL-R wet AMD registrational trials
HELIOS diabetic retinopathy program
Revenue
$14.54M
▼ 5.7% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ocular Therapeutix, Inc Q2 FY2025 Earnings Call
Confident tone
AXPAXLI registrational program / SOL trials
Trial quality, retention and rescue conduct
Label / patient population exclusions (OCT fluctuations)
Revenue
$13.46M
▼ 18.1% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Ocular Therapeutix, Inc Q4 FY2024 Earnings Call
Confident tone
AXPAXLI registrational program in wet AMD
SOL-R trial optimization and sample size reduction
FDA SPA amendment and redosing strategy
Revenue
$17.08M*
▲ 15.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Ocular Therapeutix, Inc Q3 FY2024 Earnings Call
Confident tone
AXPAXLI Wet AMD SOL-1 and SOL-R Trials
Regulatory Pathway / FDA
Diabetic Retinopathy / DME Opportunity
Revenue
$15.43M
▲ 2.3% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Ocular Therapeutix, Inc Q2 FY2024 Earnings Call
Confident tone
SOL-1 registration study enrollment
SOL-R repeat-dosing registration study
FDA alignment on study designs
Revenue
$16.44M
▲ 8.3% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ocular Therapeutix, Inc Q1 FY2024 Earnings Call
Revenue
$14.77M
▲ 10.5% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-07
Ocular Therapeutix, Inc Q3 FY2023 Earnings Call
Revenue
$15.08M
▲ 26% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Ocular Therapeutix, Inc Q2 FY2023 Earnings Call
Revenue
$15.19M
▲ 23.8% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Ocular Therapeutix, Inc Q1 FY2023 Earnings Call
Revenue
$13.37M
▲ 1.4% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ocular Therapeutix, Inc Q4 FY2022 Earnings Call
Revenue
$14.08M*
▲ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ocular Therapeutix, Inc Q3 FY2022 Earnings Call
Revenue
$11.96M
▼ 1.5% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ocular Therapeutix, Inc Q2 FY2022 Earnings Call
Revenue
$12.27M
▲ 4.7% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Ocular Therapeutix, Inc Q1 FY2022 Earnings Call
Revenue
$13.19M
▲ 79.6% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Ocular Therapeutix, Inc Q4 FY2021 Earnings Call
Revenue
$12.31M*
▲ 67.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Ocular Therapeutix, Inc Q3 FY2021 Earnings Call
Revenue
$12.15M
▲ 106.8% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Ocular Therapeutix, Inc Q2 FY2021 Earnings Call
Revenue
$11.72M
▲ 646.8% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Ocular Therapeutix, Inc Q1 FY2021 Earnings Call
Revenue
$7.34M
▲ 181.4% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Ocular Therapeutix, Inc Q4 FY2020 Earnings Call
Revenue
$7.35M*
▲ 225.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ocular Therapeutix, Inc Q3 FY2020 Earnings Call
Revenue
$5.88M
▲ 608.8% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-17
Ocular Therapeutix, Inc Q2 FY2020 Earnings Call
Revenue
$1.57M
▲ 141.4% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Ocular Therapeutix, Inc Q1 FY2020 Earnings Call
Revenue
$2.61M
▲ 430.3% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts
CIK
1393434
CUSIP
67576A100
13F (30d)
247 filings
242 filers
Visit website
Investor relations